NEW YORK (GenomeWeb News) – Barcelona-based plasma products manufacturer Grifols has acquired a 60 percent stake in Progenika Biopharma for €37 million ($48.4 million), the firms announced earlier this week.

Grifols paid 50 percent of the consideration in cash, with the other 50 percent coming in the form of non-voting (Class B) Grifols shares.

Vizcaya, Spain-based Progenika develops molecular diagnostics tests and DNA chips for disease diagnosis and prognosis. In particular, it has developed tests for evaluating transfusional compatibility studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.